MLTX
MoonLake Immunotherapeutics
Price Chart
Latest Quote
$20.00
-1.22 (-5.75%)
Current Price
| Previous Close | $21.22 |
| Open | $19.39 |
| Day High | $20.43 |
| Day Low | $18.86 |
| Volume | 5,298,871 |
Stock Information
| Shares Outstanding | 73.62M |
| Total Debt | $100.80M |
| Cash Equivalents | $357.92M |
| Net Income | $-257.08M |
| Sector | Healthcare |
| Industry | Biotechnology |
| Market Cap | $1.47B |
| EPS (TTM) | $-3.88 |
| Exchange | NCM |
đ Comprehensive Analysis
Company Data
| Enterprise Value | $1.31B |
| Income | $-257.08M |
| Book/sh | $3.52 |
| Cash/sh | $4.86 |
| Employees | 130 |
Financial Ratios
| Quick Ratio | 7.89 |
| Current Ratio | 8.60 |
| Debt/Eq | 39.68 |
Returns & Margins
| ROA | -36.66% |
| ROE | -77.85% |
Ownership
| Insider Ownership | 9.68% |
| Institutional Ownership | 87.86% |
| Insider & Institutional transactions data not available | |
Valuation Ratios
| Forward P/E | -5.80 |
| P/B | 5.68 |
Analyst Data
| Recommendation | buy |
| Target Price | $27.62 |
Technical Indicators
| SMA20 | $18.88 |
| SMA50 | $18.05 |
| SMA200 | $18.24 |
| RSI | 59.47 |
| ATR | 1.3118 |
| Shares Float | 39.63M |
| Short Float | 11.08% |
| Short Ratio | 5.92 |
| Volatility | 1.04 |
| Rel Volume | 4.43 |
Performance History
| Week | +5.37% |
| Month | +9.95% |
| Quarter | +19.69% |
| 6 Months | +49.37% |
| YTD | +67.36% |
| Year | -55.43% |
| 3 Years | -23.31% |
| 5 Years | +98.53% |
| 10 Years | +90.66% |
Stock Score:
â Premium
Based on debt, profitability, growth, and cash flow metrics
â Premium Feature
Sign up for free to view detailed scoring breakdown â premium is free during our trial period!
Recent Price History
| Date | Close | Volume |
|---|---|---|
| 2026-06-24 | $20.00 | 5,298,871 |
| 2026-06-23 | $21.22 | 1,737,300 |
| 2026-06-22 | $22.16 | 3,494,000 |
| 2026-06-18 | $19.21 | 774,500 |
| 2026-06-17 | $19.19 | 878,800 |
| 2026-06-16 | $18.98 | 811,200 |
| 2026-06-15 | $19.19 | 575,700 |
| 2026-06-12 | $18.69 | 738,200 |
| 2026-06-11 | $17.75 | 726,200 |
| 2026-06-10 | $17.49 | 695,100 |
| 2026-06-09 | $17.80 | 962,600 |
| 2026-06-08 | $18.00 | 1,213,700 |
| 2026-06-05 | $17.90 | 538,600 |
| 2026-06-04 | $18.72 | 439,700 |
| 2026-06-03 | $18.27 | 570,000 |
| 2026-06-02 | $17.87 | 1,119,800 |
| 2026-06-01 | $18.82 | 679,500 |
| 2026-05-29 | $19.18 | 1,146,600 |
| 2026-05-28 | $18.68 | 567,500 |
| 2026-05-27 | $18.41 | 928,700 |
| 2026-05-26 | $18.23 | 575,200 |
About MoonLake Immunotherapeutics
MoonLake Immunotherapeutics, a clinical-stage biotechnology company, focuses on developing therapies for inflammatory skin and joint diseases. It develops Sonelokimab, a novel tri-specific IL-17A and IL-17F inhibiting Nanobody for the treatment of inflammatory diseases in dermatology and rheumatology, as well as for hidradenitis suppurativa, psoriatic arthritis, axial spondyloarthritis, palmoplantar pustulosis, and psoriasis. The company was founded in 2021 and is headquartered in Zug, Switzerland.
đ° Latest News
Exchange-Traded Funds, Equity Futures Higher Pre-Bell Wednesday Amid Easing US-Iran Tensions
MT Newswires âĸ 2026-06-24T13:17:40ZMLTX Stock Extends Pullback After Biggest Rally In Over 6 Months Following Skin Disease Trial Data â A Look At The Latest Development
Stocktwits âĸ 2026-06-24T11:48:26Z
MLTX Stock Clocks Best Day In Over 6 Months â Whatâs Driving The Investor Optimism?
Stocktwits âĸ 2026-06-22T20:59:03Z
Why Is MLTX Stock Rallying Nearly 20% Overnight?
Stocktwits âĸ 2026-06-22T00:52:29Z
MLTX Stock Moves Higher As Traders Position For Late-Stage Trial Catalysts
Stocktwits âĸ 2026-06-17T17:29:36Z
Why Did MLTX Stock Rise After-Hours Today?
Stocktwits âĸ 2026-06-09T01:17:35Z
MoonLake Immunotherapeutics CFO Trims His Stake. Should Investors Be Concerned?
Motley Fool âĸ 2026-06-05T02:19:51Z
MoonLake Immunotherapeutics (MLTX) Price Target Raised to $45 At H.C. Wainwright on FDA Progress
Insider Monkey âĸ 2026-06-02T13:55:36Z
MoonLake Immunotherapeutics (MLTX) Is Up 7.3% After FDA Aligns on Sonelokimab BLA Pathway
Simply Wall St. âĸ 2026-05-12T16:17:29Z
MoonLake Clears A Key Regulatory Hurdle, And Shares Rocket
Investor's Business Daily âĸ 2026-05-11T20:15:19Z
Period:
Loading...
Income Statement (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Revenue | ||||
| Total Revenue | $0 | $0 | $0 | $0 |
| Operating Revenue | $0 | $0 | $0 | $0 |
| Expenses | ||||
| Interest Expense | $7,248,000 | $0 | $0 | - |
| Total Expenses | $244,834,000 | $143,091,000 | $54,123,000 | $65,061,417 |
| Other Income Expense | $22,372,000 | $22,129,000 | $10,138,000 | $591,732 |
| Other Non Operating Income Expenses | $22,372,000 | $22,129,000 | $10,138,000 | $591,732 |
| Net Non Operating Interest Income Expense | $-7,248,000 | $0 | $0 | - |
| Interest Expense Non Operating | $7,248,000 | $0 | $0 | - |
| Operating Expense | $244,834,000 | $143,091,000 | $54,123,000 | $65,061,417 |
| General And Administrative Expense | $41,972,000 | $30,320,000 | $22,321,000 | $23,012,463 |
| Income & Earnings | ||||
| Net Income From Continuing Operation Net Minority Interest | $-227,318,000 | $-118,936,000 | $-36,007,000 | $-49,973,249 |
| Net Interest Income | $-7,248,000 | $0 | $0 | - |
| Normalized Income | $-227,318,000 | $-118,936,000 | $-36,007,000 | $-49,973,249 |
| Net Income From Continuing And Discontinued Operation | $-227,318,000 | $-118,936,000 | $-36,007,000 | $-49,973,249 |
| Total Operating Income As Reported | $-244,834,000 | $-143,091,000 | $-54,123,000 | $-65,061,417 |
| Net Income Common Stockholders | $-227,318,000 | $-118,936,000 | $-36,007,000 | $-49,973,249 |
| Net Income | $-227,318,000 | $-118,936,000 | $-36,007,000 | $-49,973,249 |
| Net Income Including Noncontrolling Interests | $-230,321,000 | $-121,244,000 | $-44,079,000 | $-64,506,051 |
| Net Income Continuous Operations | $-230,321,000 | $-121,244,000 | $-44,079,000 | $-64,506,051 |
| Pretax Income | $-229,710,000 | $-120,962,000 | $-43,985,000 | $-64,469,685 |
| Operating Income | $-244,834,000 | $-143,091,000 | $-54,123,000 | $-65,061,417 |
| Per Share | ||||
| Diluted EPS | $-3.53 | $-1.89 | $-0.73 | $-1.28 |
| Basic EPS | $-3.53 | $-1.89 | $-0.73 | $-1.28 |
| Other | ||||
| Tax Effect Of Unusual Items | $0 | $0 | $0 | $0 |
| Tax Rate For Calcs | $0 | $0 | $0 | $0 |
| Normalized EBITDA (Bullshit earnings) | $-219,846,000 | $-119,577,000 | $-43,615,000 | $-64,896,634 |
| Reconciled Depreciation | $2,616,000 | $1,385,000 | $370,000 | $164,783 |
| EBITDA (Bullshit earnings) | $-219,846,000 | $-119,577,000 | $-43,615,000 | $-64,896,634 |
| EBIT | $-222,462,000 | $-120,962,000 | $-43,985,000 | $-65,061,417 |
| Diluted Average Shares | $64,463,889 | $62,870,237 | $49,122,534 | $38,977,600 |
| Basic Average Shares | $64,463,889 | $62,870,237 | $49,122,534 | $38,977,600 |
| Diluted NI Availto Com Stockholders | $-227,318,000 | $-118,936,000 | $-36,007,000 | $-49,973,249 |
| Minority Interests | $3,003,000 | $2,308,000 | $8,072,000 | $14,532,802 |
| Tax Provision | $611,000 | $282,000 | $94,000 | $36,366 |
| Research And Development | $202,862,000 | $112,771,000 | $31,802,000 | $42,048,954 |
| Selling General And Administration | $41,972,000 | $30,320,000 | $22,321,000 | $23,012,463 |
| Other Gand A | $41,972,000 | $30,320,000 | $22,321,000 | $23,012,463 |
Fetched: 2026-06-15
Balance Sheet (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Assets | ||||
| Net Tangible Assets | $304,481,000 | $446,825,000 | $495,675,683 | $48,898,296 |
| Total Assets | $424,433,000 | $477,933,000 | $526,540,115 | $76,843,301 |
| Total Non Current Assets | $2,739,000 | $3,644,000 | $12,372,813 | $331,969 |
| Other Non Current Assets | $596,000 | - | - | - |
| Current Assets | $421,694,000 | $474,289,000 | $514,167,302 | $76,511,332 |
| Prepaid Assets | $22,857,000 | $23,418,000 | $2,102,203 | $4,179,468 |
| Receivables | $4,869,000 | $2,844,000 | $1,056,862 | $217,129 |
| Other Receivables | $4,869,000 | $2,844,000 | $1,056,862 | $217,129 |
| Cash Cash Equivalents And Short Term Investments | $393,968,000 | $448,027,000 | $511,008,237 | $72,114,735 |
| Cash And Cash Equivalents | $334,517,000 | $180,426,000 | $451,169,337 | $39,505,627 |
| Non Current Prepaid Assets | - | $0 | $8,423,468 | $0 |
| Cash Financial | - | - | - | - |
| Debt | ||||
| Total Debt | $75,708,000 | $2,830,000 | $3,697,866 | $282,580 |
| Long Term Debt And Capital Lease Obligation | $74,474,000 | $1,458,000 | $2,499,990 | $128,951 |
| Long Term Debt | $74,100,000 | - | - | - |
| Current Debt And Capital Lease Obligation | $1,234,000 | $1,372,000 | $1,197,876 | $153,629 |
| Net Debt | - | - | - | - |
| Current Debt | - | - | - | - |
| Other Current Borrowings | - | - | - | - |
| Liabilities | ||||
| Total Liabilities Net Minority Interest | $119,952,000 | $24,542,000 | $13,049,096 | $8,076,603 |
| Total Non Current Liabilities Net Minority Interest | $74,474,000 | $2,079,000 | $3,083,416 | $411,157 |
| Current Liabilities | $45,478,000 | $22,463,000 | $9,965,680 | $7,665,446 |
| Payables And Accrued Expenses | $41,920,000 | $16,854,000 | $5,987,585 | $6,402,083 |
| Payables | $30,647,000 | $9,634,000 | $2,205,660 | $364,798 |
| Other Payable | $1,127,000 | $314,000 | $372,771 | $157,306 |
| Total Tax Payable | $1,094,000 | $642,000 | $367,976 | $109,826 |
| Accounts Payable | $28,426,000 | $8,678,000 | $1,464,913 | $97,666 |
| Equity | ||||
| Common Stock Equity | $304,481,000 | $446,825,000 | $495,675,683 | $48,898,296 |
| Total Equity Gross Minority Interest | $304,481,000 | $453,391,000 | $513,491,019 | $68,766,698 |
| Stockholders Equity | $304,481,000 | $446,825,000 | $495,675,683 | $48,898,296 |
| Gains Losses Not Affecting Retained Earnings | $604,000 | $4,997,000 | $2,357,621 | $350,946 |
| Other Equity Adjustments | $604,000 | $4,997,000 | $2,357,621 | $350,946 |
| Retained Earnings | $-462,911,000 | $-235,593,000 | $-116,657,472 | $-80,650,212 |
| Preferred Stock Equity | - | - | - | - |
| Other | ||||
| Ordinary Shares Number | $71,373,579 | $63,077,431 | $60,466,453 | $38,977,600 |
| Share Issued | $71,373,579 | $63,077,431 | $60,466,453 | $38,977,600 |
| Tangible Book Value | $304,481,000 | $446,825,000 | $495,675,683 | $48,898,296 |
| Invested Capital | $378,581,000 | $446,825,000 | $495,675,683 | $48,898,296 |
| Working Capital | $376,216,000 | $451,826,000 | $504,201,622 | $68,845,886 |
| Capital Lease Obligations | $1,608,000 | $2,830,000 | $3,697,866 | $282,580 |
| Total Capitalization | $378,581,000 | $446,825,000 | $495,675,683 | $48,898,296 |
| Minority Interest | $0 | $6,566,000 | $17,815,336 | $19,868,402 |
| Additional Paid In Capital | $766,781,000 | $677,415,000 | $609,969,236 | $129,192,291 |
| Capital Stock | $7,000 | $6,000 | $6,298 | $5,271 |
| Common Stock | $7,000 | $6,000 | $6,298 | $5,271 |
| Employee Benefits | $0 | $621,000 | $583,426 | $282,206 |
| Non Current Pension And Other Postretirement Benefit Plans | $0 | $621,000 | $583,426 | $282,206 |
| Long Term Capital Lease Obligation | $374,000 | $1,458,000 | $2,499,990 | $128,951 |
| Current Capital Lease Obligation | $1,234,000 | $1,372,000 | $1,197,876 | $153,629 |
| Pensionand Other Post Retirement Benefit Plans Current | $2,324,000 | $4,237,000 | $2,780,219 | $1,109,734 |
| Current Accrued Expenses | $11,273,000 | $7,220,000 | $3,781,925 | $6,037,285 |
| Net PPE | $2,143,000 | $3,644,000 | $3,949,345 | $331,969 |
| Gross PPE | $2,143,000 | $3,644,000 | $3,949,345 | $331,969 |
| Other Properties | $577,000 | $722,000 | $320,865 | $331,969 |
| Buildings And Improvements | $1,566,000 | $2,922,000 | $3,628,480 | $282,580 |
| Properties | $0 | $0 | $0 | $0 |
| Other Short Term Investments | $59,451,000 | $267,601,000 | $59,838,900 | $32,609,108 |
| Treasury Shares Number | - | - | $0 | - |
| Preferred Stock | - | - | $0 | $0 |
| Treasury Stock | - | - | - | $0 |
Fetched: 2026-06-15
Cash Flow Statement (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Free Cash Flow | ||||
| Free Cash Flow | $-196,042,000 | $-117,107,000 | $-43,062,000 | $-55,909,909 |
| Operating Activities | ||||
| Operating Cash Flow | $-196,007,000 | $-116,587,000 | $-42,778,000 | $-55,893,900 |
| Cash Flow From Continuing Operating Activities | $-196,007,000 | $-116,587,000 | $-42,778,000 | $-55,893,900 |
| Operating Gains Losses | $-58,000 | $1,000 | $-85,000 | $304,031 |
| Investing Activities | ||||
| Capital Expenditure | $-35,000 | $-520,000 | $-284,000 | $-16,009 |
| Investing Cash Flow | $202,992,000 | $-205,596,000 | $-25,184,000 | $-32,340,593 |
| Cash Flow From Continuing Investing Activities | $202,992,000 | $-205,596,000 | $-25,184,000 | $-32,340,593 |
| Financing Activities | ||||
| Issuance Of Capital Stock | $72,395,000 | $52,540,000 | $482,454,000 | $0 |
| Financing Cash Flow | $145,997,000 | $51,312,000 | $479,701,000 | $119,692,735 |
| Cash Flow From Continuing Financing Activities | $145,997,000 | $51,312,000 | $479,701,000 | $119,692,735 |
| Net Common Stock Issuance | $72,395,000 | $52,540,000 | $482,454,000 | $0 |
| Common Stock Issuance | $72,395,000 | $52,540,000 | $482,454,000 | $0 |
| Repurchase Of Capital Stock | - | $-50 | $0 | $0 |
| Net Other Financing Charges | - | $-1,470,000 | $-2,753,000 | $134,688,944 |
| Net Preferred Stock Issuance | - | - | - | $0 |
| Preferred Stock Issuance | - | - | - | $0 |
| Other | ||||
| Issuance Of Debt | $73,022,000 | $0 | $0 | $0 |
| Interest Paid Supplemental Data | $5,059,000 | $0 | $0 | - |
| End Cash Position | $334,517,000 | $180,426,000 | $451,169,000 | $39,505,627 |
| Beginning Cash Position | $180,426,000 | $451,169,000 | $39,506,000 | $8,038,845 |
| Effect Of Exchange Rate Changes | $1,109,000 | $128,000 | $-76,000 | $8,540 |
| Changes In Cash | $152,982,000 | $-270,871,000 | $411,739,000 | $31,458,242 |
| Proceeds From Stock Option Exercised | $580,000 | $242,000 | $0 | $3,791 |
| Net Issuance Payments Of Debt | $73,022,000 | $0 | $0 | $-15,000,000 |
| Net Long Term Debt Issuance | $73,022,000 | $0 | $0 | $-15,000,000 |
| Long Term Debt Issuance | $73,022,000 | $0 | $0 | - |
| Net Investment Purchase And Sale | $203,027,000 | $-205,076,000 | $-24,900,000 | $-32,324,584 |
| Sale Of Investment | $468,401,000 | $145,203,000 | $150,833,000 | $9,901,437 |
| Purchase Of Investment | $-265,374,000 | $-350,279,000 | $-175,733,000 | $-42,226,021 |
| Net PPE Purchase And Sale | $-35,000 | $-520,000 | $-284,000 | $-16,009 |
| Purchase Of PPE | $-35,000 | $-520,000 | $-284,000 | $-16,009 |
| Change In Working Capital | $19,878,000 | $-3,784,000 | $-6,218,000 | $-1,579,895 |
| Change In Other Current Liabilities | $-1,222,000 | $-1,423,000 | $-222,000 | $-152,425 |
| Change In Other Current Assets | $-587,000 | $-6,000 | $-66,000 | $0 |
| Change In Payables And Accrued Expense | $23,151,000 | $12,324,000 | $1,256,000 | $1,371,258 |
| Change In Accrued Expense | $2,591,000 | $5,169,000 | $-327,000 | $2,685,576 |
| Change In Payable | $20,560,000 | $7,155,000 | $1,583,000 | $-1,314,318 |
| Change In Prepaid Assets | $561,000 | $-12,893,000 | $-6,346,000 | $-2,730,373 |
| Change In Receivables | $-2,025,000 | $-1,786,000 | $-840,000 | $-68,355 |
| Other Non Cash Items | $-1,020,000 | $-227,000 | $128,000 | $68,454 |
| Stock Based Compensation | $12,898,000 | $7,282,000 | $7,106,000 | $9,654,778 |
| Depreciation Amortization Depletion | $2,616,000 | $1,385,000 | $370,000 | $164,783 |
| Depreciation And Amortization | $2,616,000 | $1,385,000 | $370,000 | $164,783 |
| Pension And Employee Benefit Expense | $-58,000 | $1,000 | $-85,000 | $304,031 |
| Net Income From Continuing Operations | $-230,321,000 | $-121,244,000 | $-44,079,000 | $-64,506,051 |
| Repayment Of Debt | - | $0 | $0 | $-15,000,000 |
| Income Tax Paid Supplemental Data | - | $147,294 | $41,713 | $4,312 |
| Common Stock Payments | - | $-50 | $0 | $0 |
| Long Term Debt Payments | - | $0 | $0 | $-15,000,000 |
| Change In Other Working Capital | - | - | $-65,513 | - |
| Depreciation | - | - | $13,158 | $12,358 |
| Net Short Term Debt Issuance | - | - | - | $0 |
| Short Term Debt Issuance | - | - | - | $0 |
Fetched: 2026-06-15